89 related articles for article (PubMed ID: 19376320)
1. Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study.
Suh JW; Baek SH; Park JS; Kang HJ; Chae IH; Choi DJ; Park HJ; Kim PJ; Seung KB; Kim HS
Am Heart J; 2009 May; 157(5):908-12. PubMed ID: 19376320
[TBL] [Abstract][Full Text] [Related]
2. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection).
Wang Y; Zhang W; Zhang Y; Yang Y; Sun L; Hu S; Chen J; Zhang C; Zheng Y; Zhen Y; Sun K; Fu C; Yang T; Wang J; Sun J; Wu H; Glasgow WC; Hui R
Circulation; 2006 Mar; 113(12):1615-21. PubMed ID: 16549638
[TBL] [Abstract][Full Text] [Related]
3. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study.
Lacut K; Larramendy-Gozalo C; Le Gal G; Duchemin J; Mercier B; Gourhant L; Mottier D; Becquemont L; Oger E; Verstuyft C
J Thromb Haemost; 2007 Oct; 5(10):2020-4. PubMed ID: 17883698
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion.
Ortak H; Söğüt E; Demir H; Ardagil A; Benli I; Sahin S
Clin Exp Ophthalmol; 2012; 40(7):743-8. PubMed ID: 22394334
[TBL] [Abstract][Full Text] [Related]
5. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
[TBL] [Abstract][Full Text] [Related]
6. Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke.
Shyu HY; Fong CS; Fu YP; Shieh JC; Yin JH; Chang CY; Wang HW; Cheng CW
Clin Chim Acta; 2010 Jun; 411(11-12):840-5. PubMed ID: 20193673
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
[TBL] [Abstract][Full Text] [Related]
8. Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.
Giansante C; Fiotti N; Altamura N; Pitacco P; Consoloni L; Scardi S; Mazzone C; Grassi G; Pandullo C; Di Lenarda A
J Thromb Thrombolysis; 2012 Nov; 34(4):506-12. PubMed ID: 22592842
[TBL] [Abstract][Full Text] [Related]
9. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry.
Berger PB; Kleiman NS; Pencina MJ; Hsieh WH; Steinhubl SR; Jeremias A; Sonel A; Browne K; Barseness G; Cohen DJ;
JACC Cardiovasc Interv; 2010 Sep; 3(9):920-7. PubMed ID: 20850090
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation.
Auer J; Leitner A; Berent R; Lamm G; Lassnig E; Krennmair G
Atherosclerosis; 2010 Jun; 210(2):503-9. PubMed ID: 20060973
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis.
Giustino G; Baber U; Salianski O; Sartori S; Stone GW; Leon MB; Aquino M; Stefanini GG; Steg PG; Windecker S; O' Donoghue M; Wijns W; Serruys PW; Valgimigli M; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari D; Von Birgelen C; Dangas GD; Cha JY; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Genereux P; Chieffo A; Mehran R
Circ Cardiovasc Interv; 2016 Jan; 9(1):e002995. PubMed ID: 26747850
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: A pilot study.
Holzer G; Grasse AV; Zehetmayer S; Bencur P; Bieglmayer C; Mannhalter C
Transl Res; 2010 Jul; 156(1):37-44. PubMed ID: 20621035
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation.
Park DW; Yun SC; Lee JY; Kim WJ; Kang SJ; Lee SW; Kim YH; Lee CW; Kim JJ; Park SW; Park SJ
Circulation; 2009 Nov; 120(20):1987-95. PubMed ID: 19884467
[TBL] [Abstract][Full Text] [Related]
14. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
[TBL] [Abstract][Full Text] [Related]
15. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
Butler MJ; Eccleston D; Clark DJ; Ajani AE; Andrianopoulos N; Brennan A; New G; Black A; Szto G; Reid CM; Yan BP; Shaw JA; Dart AM; Duffy SJ;
Am Heart J; 2009 May; 157(5):899-907. PubMed ID: 19376319
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
17. Incidence and very long- term outcomes of stent thrombosis after bare-metal or drug-eluting stent implantation: a retrospective analysis.
Pullara A; Longo G; Gonella A; D'Ascenzo F; Biondi Zoccai G; Moretti C; Sciuto F; Omedè PL; Bollati M; Gaita F; Sheiban I
Minerva Cardioangiol; 2013 Feb; 61(1):1-9. PubMed ID: 23381375
[TBL] [Abstract][Full Text] [Related]
18. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study.
Teichert M; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; De Smet PA; Witteman JC; Stricker BH
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):771-6. PubMed ID: 18218987
[TBL] [Abstract][Full Text] [Related]
20. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
